Loomis, Sayles & Company
ACAD icon

Loomis, Sayles & Company’s Acadia Pharmaceuticals ACAD Stock Holding History

Loomis, Sayles & Company’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-287,133
Closed -$15.3M – 832
2020
Q4 		$15.3M Buy
+287,133
New +$14.3M 0.02% 298
2020
Q3 		– Sell
-198,031
Closed -$9.6M – 646
2020
Q2 		$9.6M Buy
+198,031
New +$9.51M 0.02% 320
2013
Q4 		– Sell
-61,418
Closed -$1.69M – 756
2013
Q3 		$1.69M Buy
+61,418
New +$1.28M 0.01% 593

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Loomis, Sayles & Company's ACAD Position: Q1 2021 in Review

Loomis, Sayles & Company sold out of Acadia Pharmaceuticals (ACAD) in Q1 2021, closing a stake of 287,133 shares — an estimated $15.3M sold.

Loomis, Sayles & Company first reported a position in ACAD in Q3 2013 and held it in 3 quarters. The position peaked at $15.3M in Q4 2020. 272 funds tracked by Wall St. Rank hold ACAD as of Q1 2021.

  • Loomis, Sayles & Company reported no remaining Acadia Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Loomis, Sayles & Company sold 287,133 Acadia Pharmaceuticals shares in Q1 2021, an estimated $15.3M.
  • Loomis, Sayles & Company first reported a position in Acadia Pharmaceuticals in Q3 2013 and held it in 3 quarters.
  • Loomis, Sayles & Company's Acadia Pharmaceuticals position peaked at $15.3M in Q4 2020.
  • 272 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2021.

Based on Loomis, Sayles & Company's 13F filing for Q1 2021, filed 17 May 2021.